Skip to main content
U.S. flag

An official website of the United States government

Milestone 4.U

AD Related Dementias – Specific

Incorporate VCID findings from basic science into the design of clinical research and trials targeting VCID-relevant cognitive impairment and dementia.


Success Criteria

  • Support VCID clinical research and trials informed by basic VCID science research outcomes, e.g. biomarkers that emerge from basic studies, and basic mechanisms such as (but not limited to) glymphatic and intramural periarterial drainage (IPAD).

Summary of Key Accomplishments

A strong body of evidence suggests that individuals who have vascular brain damage (e.g., white matter damage) as well as individuals who have had a stroke are at increased risk of cognitive decline and dementia. In addition, building on a rich body of basic research on blood clotting mechanisms and proteins, researchers developed a drug that protects rat and mouse brains from brain bleeds during ischemic stroke as well as later white matter damage. The drug, known as “3K3A-APC”, was recently shown in an NINDS-supported Phase 2 clinical trial (RHAPSODY) to be safe in humans and protect from brain bleeds due to ischemic stroke. The drug manufacturer is planning to launch a Phase 3 trial shortly focused on ischemic stroke treatment. Future findings from controlled clinical trials on 3K3A-APC could include data on cognitive and dementia-related outcomes, illustrating a promising basic science to bedside story of a potential treatment of human brain vascular disease.

This information is current as of July 2022.


Research Implementation Area
AD Related Dementias - Specific
Timeline
2020–2027
Status
In Progress

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Relevant Recommendations

nia.nih.gov

An official website of the National Institutes of Health